MedTrace Logo

Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

NCT00920387 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-07-12

Study results available
· View outcomes & findings →

Summary

This study will find out whether psychotherapy combined with lysergic acid diethylamide (LSD) is safe and is helpful in people who are anxious because they have a potentially fatal disease. The study will measure anxiety and quality of life before and after people have two sessions with either full or active placebo dose of LSD. They expect LSD-assisted psychotherapy to reduce anxiety and improve quality of life.

Conditions

Interventions

DRUG

200 mcg LSD

Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session

DRUG

20 mcg LSD

Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session

BEHAVIORAL

Therapy

Therapy provided by male and female co-therapists

Sponsors & Collaborators

  • Multidisciplinary Association for Psychedelic Studies

    lead OTHER

Principal Investigators

  • Peter Gasser, MD · Private practices of Peter Gasser; Swiss Medical Association for Psycholytic Therapy (SAPT)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2011-04-14
Completion
2012-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920387 on ClinicalTrials.gov